Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.54 |
| ▸ | EGFR | P00533 | 4/20 | 0.54 |
| ▸ | KIT | P10721 | 3/20 | 0.54 |
| ▸ | NEK2 | P51955 | 3/20 | 0.54 |
| ▸ | MELK | Q14680 | 2/20 | 0.54 |
| ▸ | PRKAA1 | Q13131 | 12/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 11/20 | 0.50 |
| ▸ | FLT3 | P36888 | 5/20 | 0.50 |
| ▸ | PLK4 | O00444 | 3/20 | 0.50 |
| ▸ | DCLK1 | O15075 | 3/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.50 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.50 |
| ▸ | INSR | P06213 | 3/20 | 0.50 |
| ▸ | LCK | P06239 | 3/20 | 0.50 |
| ▸ | CSF1R | P07333 | 3/20 | 0.50 |
| ▸ | RET | P07949 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143534 | 0.88 | KDR (0.72) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL147703 | 0.84 | KDR (0.55) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL6514631 | 0.84 | KDR (0.56) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL143688 | 0.82 | SRC (0.53) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL3802797 | 0.81 | KDR (0.53) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL3802793 | 0.81 | KDR (0.53) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL13755247 | 0.80 | KDR (0.74) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL30452515 | 0.80 | KDR (0.74) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL141545 | 0.80 | RET (0.61) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL147115 | 0.80 | KDR (0.55) | KDRPDGFRBFGFR1EGFRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | KDR 1077/4885PDGFRB 467/4885FGFR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.